公开(公告)号：US20240335538A1

公开(公告)日：2024-10-10

申请号：US18290668

申请日：2022-07-21

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Tae-Don KIM ,  Sooyun LEE

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K14/73 ,  C07K14/735 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0783

CPC classification number: A61K39/464404 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4614 ,  A61K39/4615 ,  A61K39/4631 ,  A61K39/464406 ,  A61K39/464411 ,  A61K39/464419 ,  A61K39/464429 ,  A61K39/464466 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70532 ,  C07K14/70535 ,  C07K14/7056 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/70596 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/303 ,  C07K16/32 ,  C12N5/0646 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00

Abstract: The present invention relates to: a novel chimeric antigen receptor containing, as an intracellular signaling domain, an intracellular domain of a receptor containing a dead region; and immune cells expressing the chimeric antigen receptor. In environments in which normal cells are present, the immune cells expressing the chimeric antigen receptor according to the present invention exhibit little or no cytotoxicity and cell death of the immune cells is exhibited, thus ensuring the stability of the normal cells. Conversely, in environments in which target cells are present, the immune cells exhibit more potent cytotoxicity than with conventional techniques utilizing a lone chimeric antigen receptor.

公开(公告)号：US20240216428A1

公开(公告)日：2024-07-04

申请号：US18288815

申请日：2022-04-27

Applicant: Korea Research Institute of Bioscience and Biotechnology

Inventor： Tae-Don KIM ,  Seona CHO ,  Sooyun LEE

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/02 ,  C07K14/725 ,  C07K16/28 ,  C12N15/86

CPC classification number: A61K35/17 ,  A61K39/4613 ,  A61P35/02 ,  C07K14/7051 ,  C07K16/2896 ,  C12N15/86 ,  A61K2239/13 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2740/15043

Abstract: The present invention relates to a CD5 antibody and a chimeric antigen receptor (CAR) including the same. The chimeric antigen receptor of the present invention may be expressed in an immune cell to be utilized for an immuno-oncology therapy having reduced toxicity against a normal T cell.